A detailed history of Tower Research Capital LLC (Trc) transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,705 shares of DSGN stock, worth $10,178. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,705
Previous 6,042 71.78%
Holding current value
$10,178
Previous $20,000 55.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.19 - $5.88 $13,835 - $25,501
-4,337 Reduced 71.78%
1,705 $9,000
Q2 2024

Aug 13, 2024

BUY
$3.23 - $4.77 $10,868 - $16,051
3,365 Added 125.7%
6,042 $20,000
Q1 2024

May 15, 2024

SELL
$2.27 - $4.03 $42,735 - $75,868
-18,826 Reduced 87.55%
2,677 $10,000
Q4 2023

Feb 13, 2024

BUY
$1.99 - $2.76 $9,916 - $13,753
4,983 Added 30.16%
21,503 $56,000
Q3 2023

Nov 14, 2023

BUY
$2.05 - $8.14 $23,000 - $91,330
11,220 Added 211.7%
16,520 $38,000
Q2 2023

Aug 14, 2023

BUY
$4.99 - $7.64 $15,972 - $24,455
3,201 Added 152.5%
5,300 $33,000
Q1 2023

May 09, 2023

SELL
$5.5 - $9.77 $6,281 - $11,157
-1,142 Reduced 35.24%
2,099 $12,000
Q4 2022

Feb 10, 2023

SELL
$7.86 - $17.2 $45,344 - $99,226
-5,769 Reduced 64.03%
3,241 $33,000
Q3 2022

Nov 10, 2022

BUY
$14.09 - $25.57 $41,579 - $75,457
2,951 Added 48.7%
9,010 $151,000
Q2 2022

Aug 15, 2022

BUY
$9.91 - $17.33 $56,179 - $98,243
5,669 Added 1453.59%
6,059 $85,000
Q1 2022

May 12, 2022

SELL
$11.17 - $20.89 $9,840 - $18,404
-881 Reduced 69.32%
390 $6,000
Q4 2021

Feb 14, 2022

BUY
$13.64 - $21.41 $11,253 - $17,663
825 Added 184.98%
1,271 $27,000
Q3 2021

Nov 15, 2021

SELL
$13.99 - $20.03 $23,545 - $33,710
-1,683 Reduced 79.05%
446 $7,000
Q2 2021

Aug 16, 2021

BUY
$19.02 - $29.78 $32,923 - $51,549
1,731 Added 434.92%
2,129 $42,000
Q1 2021

May 17, 2021

BUY
$29.52 - $41.49 $11,748 - $16,513
398 New
398 $12,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $333M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.